Izotropic’s IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies
Izotropic Corporation (OTCQB: IZOZF) has positioned its flagship device, IzoView Breast CT Imaging System, as a disruptive technology in the breast imaging market. The device, targeting a $500,000 price point, bridges the gap between Digital Breast Tomosynthesis (DBT) and MRI technologies.
IzoView offers true 3D imaging without breast compression and provides 100x greater spatial resolution compared to MRI. The device is entering the global breast imaging market, projected to grow from $5.4 billion in 2024 to $8.69 billion by 2030 at an 8.25% CAGR.
The system's initial indication targets adjunct screening for dense breast tissue patients, with 14 potential future indications across screening, diagnosis, monitoring, planning, and personalized medicine. IzoView's modular design enables software upgrades without core system replacement, creating a recurring revenue model with patent protections extending into the 2040s.
Izotropic Corporation (OTCQB: IZOZF) ha posizionato il suo dispositivo di punta, il Sistema di Imaging Mammario IzoView Breast CT, come una tecnologia rivoluzionaria nel mercato dell'imaging mammario. Il dispositivo, con un prezzo previsto di 500.000 dollari, colma il divario tra la Tomosintesi Digitale del Seno (DBT) e le tecnologie MRI.
IzoView offre un vero imaging 3D senza compressione del seno e garantisce una risoluzione spaziale 100 volte superiore rispetto alla risonanza magnetica. Il dispositivo si sta affacciando al mercato globale dell'imaging mammario, stimato in crescita da 5,4 miliardi di dollari nel 2024 a 8,69 miliardi entro il 2030 con un CAGR dell'8,25%.
L'indicazione iniziale del sistema è rivolta allo screening aggiuntivo per pazienti con tessuto mammario denso, con 14 potenziali indicazioni future che spaziano dallo screening alla diagnosi, monitoraggio, pianificazione e medicina personalizzata. Il design modulare di IzoView permette aggiornamenti software senza sostituire il sistema centrale, creando un modello di entrate ricorrenti con protezioni brevettuali che si estendono fino agli anni '40 del 2040.
Izotropic Corporation (OTCQB: IZOZF) ha posicionado su dispositivo principal, el Sistema de Imagen Mamaria IzoView Breast CT, como una tecnología disruptiva en el mercado de imagen mamaria. El dispositivo, con un precio objetivo de 500,000 dólares, cierra la brecha entre la Tomosíntesis Digital de Mama (DBT) y las tecnologías de resonancia magnética (MRI).
IzoView ofrece imagen 3D real sin compresión mamaria y proporciona una resolución espacial 100 veces mayor en comparación con la resonancia magnética. El dispositivo está ingresando al mercado global de imagen mamaria, proyectado para crecer de 5.4 mil millones de dólares en 2024 a 8.69 mil millones para 2030 con una tasa compuesta anual de crecimiento (CAGR) del 8.25%.
La indicación inicial del sistema se enfoca en el cribado complementario para pacientes con tejido mamario denso, con 14 posibles indicaciones futuras que abarcan cribado, diagnóstico, monitoreo, planificación y medicina personalizada. El diseño modular de IzoView permite actualizaciones de software sin reemplazo del sistema principal, creando un modelo de ingresos recurrentes con protecciones de patentes que se extienden hasta la década de 2040.
Izotropic Corporation (OTCQB: IZOZF)는 자사의 대표 장치인 IzoView 유방 CT 영상 시스템을 유방 영상 시장에서 혁신적인 기술로 자리매김했습니다. 이 장치는 50만 달러 가격대를 목표로 하여 디지털 유방 톰소시스(DBT)와 MRI 기술 간의 격차를 메우고 있습니다.
IzoView는 유방 압박 없이 진정한 3D 영상을 제공하며 MRI에 비해 100배 높은 공간 해상도를 자랑합니다. 이 장치는 2024년 54억 달러에서 2030년 86.9억 달러까지, 연평균 성장률 8.25%로 성장할 것으로 예상되는 글로벌 유방 영상 시장에 진입하고 있습니다.
시스템의 초기 적용 대상은 조밀한 유방 조직 환자를 위한 보조 스크리닝이며, 14가지 잠재적 미래 적용 분야가 스크리닝, 진단, 모니터링, 계획 수립 및 맞춤 의학 전반에 걸쳐 있습니다. IzoView의 모듈형 설계는 핵심 시스템 교체 없이 소프트웨어 업그레이드를 가능하게 하여 2040년대까지 특허 보호를 받는 반복 수익 모델을 창출합니다.
Izotropic Corporation (OTCQB : IZOZF) a positionné son dispositif phare, le Système d’Imagerie TDM Mammaire IzoView, comme une technologie disruptive sur le marché de l’imagerie mammaire. L’appareil, ciblant un prix de 500 000 dollars, comble le fossé entre la tomosynthèse mammaire numérique (DBT) et les technologies IRM.
IzoView offre une imagerie 3D véritable sans compression mammaire et fournit une résolution spatiale 100 fois supérieure à celle de l’IRM. L’appareil entre sur le marché mondial de l’imagerie mammaire, dont la valeur devrait passer de 5,4 milliards de dollars en 2024 à 8,69 milliards d’ici 2030, avec un taux de croissance annuel composé (CAGR) de 8,25 %.
La première indication du système cible le dépistage complémentaire pour les patientes à tissu mammaire dense, avec 14 indications potentielles futures couvrant le dépistage, le diagnostic, le suivi, la planification et la médecine personnalisée. La conception modulaire d’IzoView permet des mises à jour logicielles sans remplacement du système principal, créant un modèle de revenus récurrents avec des protections par brevet s’étendant jusque dans les années 2040.
Izotropic Corporation (OTCQB: IZOZF) hat sein Flaggschiff-Gerät, das IzoView Brust-CT-Bildgebungssystem, als disruptive Technologie im Brustbildgebungsmarkt positioniert. Das Gerät, mit einem Preisziel von 500.000 US-Dollar, schließt die Lücke zwischen Digitaler Brust-Tomosynthese (DBT) und MRT-Technologien.
IzoView bietet echte 3D-Bildgebung ohne Brustkompression und liefert eine 100-fach höhere räumliche Auflösung im Vergleich zur MRT. Das Gerät betritt den globalen Markt für Brustbildgebung, der von 5,4 Milliarden US-Dollar im Jahr 2024 auf 8,69 Milliarden US-Dollar bis 2030 bei einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 8,25 % wächst.
Die erste Indikation des Systems richtet sich auf die ergänzende Untersuchung bei Patientinnen mit dichtem Brustgewebe, mit 14 potenziellen zukünftigen Indikationen in den Bereichen Screening, Diagnose, Überwachung, Planung und personalisierte Medizin. Das modulare Design von IzoView ermöglicht Software-Updates ohne Austausch des Kernsystems und schafft ein wiederkehrendes Einnahmemodell mit Patentschutz, der bis in die 2040er Jahre reicht.
- Target price of $500K is 40-67% lower than competing breast CT systems ($825K-$1.5M)
- Performance comparable to MRI with 100x greater spatial resolution
- 10-second imaging session potentially reducing $8B annual spending on follow-up imaging
- 14 identified future indications for use with software upgrade capability
- Strategic patent portfolio extending into 2040s
- Entering high-growth market projected to reach $8.69B by 2030
- Initial market entry limited to adjunct screening indication only
- New technology requiring market education and adoption
- Emerging reimbursement status compared to established technologies
- IzoView positioned to disrupt high-growth breast imaging markets with target device price of USD
- IzoView to launch into projected fastest-growing imaging category with potential to displace well-established technologies
- Differentiated from existing device types through upgradeability, pipeline, and platform business model
VANCOUVER, British Columbia, and SACRAMENTO, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- via IBN - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides an educational overview of how its flagship device, the IzoView Breast CT Imaging System (“IzoView”), compares to existing breast imaging technologies. IzoView stands apart in terms of clinical performance, cost, and commercial positioning and holds tremendous potential to displace or complement standard-of-care modalities in a growing global market.
Breast Imaging Devices in Use Today
The breast imaging market is dominated by traditional mammography, digital breast tomosynthesis (“DBT”, “3D mammography”), ultrasound, and MRI technologies, each of which has established clinical applications with well-known limitations. Mammography and DBT remain the primary 2D-based screening tools, yet their sensitivity decreases in approximately
Ultrasound is often used as a supplemental imaging tool for dense breasts, but it often returns high false-positive rates and can be dependent on operator skill. Automated breast ultrasound (“ABUS”) has been designed to eliminate operator-dependency, but any abnormalities still need to be verified by handheld ultrasound, adding more steps to the workflow.
Contrast-enhanced mammography (“CE-mammo”) is a dedicated system, not simply the addition of injectable contrast to conventional mammography machines. CE-mammo intends to compensate for the limitations of its 2D, compression-based design with the addition of contrast, but cannot provide the same high-value clinical information that comes with true 3D imaging.
Molecular breast imaging (“MBI”) is an emerging modality that uses gamma radiation and injectable radioactive tracers. It is typically reserved for investigational diagnostic imaging and delivers a higher dose than x-ray-based systems like mammography, DBT, and breast CT.
Breast MRI and its faster variant, abbreviated MRI, are highly sensitive but costly, time-consuming, and generally reserved for high-risk patients. MRI machines are not breast dedicated, and competition with other medical specialties persists, leading to long wait times.
IzoView: Bridging the Gap Between DBT and MRI
IzoView, developed with the global licensing rights to breast CT technology from The Regents of the University of California (“UC Davis”), is positioned as a new category in breast imaging that bridges the gap between DBT and MRI, offering true 3D imaging without breast compression. Unlike compression-based mammography and DBT, IzoView images the breast in its natural shape, delivering ultra-high-resolution, contrast-enhanced imaging that serves as a powerful alternative for breast cancer screening, including for high-risk patients. Compared to MRI, IzoView offers 100x greater spatial resolution. Breast CT technology, in academic research trials conducted at UC Davis, has been shown to have performance comparable to MRI2, and “may offer more accurate margin analysis, improved lesion characterization, and superior visualization of microcalcifications3”. With a shorter scan time and a target sales price significantly below MRI, IzoView is designed for greater accessibility across imaging centers of various sizes and resource levels.
IzoView vs the Rest: Comparing the Breast Imaging Technologies
Breast cancer imaging methods vary widely in performance, cost, and availability, impacting how and where they are used across patient populations. Below are comparisons of breast cancer imaging modalities. Costs for devices and imaging exams are taken from public information available online. The Company acknowledges there may be outliers to these averages.
Chart 1: Breast Imaging Modalities: Technical & Clinical Attributes
| Modality | True 3D Imaging | Radiation | Primary Use | AI Integrations |
| Mammography | No | Yes (low-dose X-ray) | Screening | Yes |
| Tomosynthesis (“DBT”) | No (15°-50°) | Yes (low-dose X-ray) | Screening & Diagnostic | Yes |
| Ultrasound (Handheld) | Yes | No | Supplemental Imaging Tool | Limited |
| Automated Breast Ultrasound | Yes | No | Supplemental Screening Tool | Limited |
| Molecular Breast Imaging (“MBI”) | Yes | Yes (Gamma Radiation) | Investigational Diagnostic Tool | Emerging |
| Contrast-Enhanced Mammography | No | Yes (low-dose X-ray) | Diagnostic | Emerging |
| Breast MRI | Yes | No | High Risk Screening & Diagnostic | Yes |
| Abbreviated MRI | Yes | No | Supplemental Screening | Yes |
| IzoView Breast CT | Yes (360°) | Yes (low-dose X-ray) | Adjunctive Screening (Initial Indication for Use) | Yes & Emerging |
Chart 2: Cost, Access & Adoption Factors
| Modality | Average Device Cost USD | Avg. Exam Cost | Availability | Reimbursement Trends |
| Mammography | Widely available | Widely Covered | ||
| Tomosynthesis (DBT) | Widely available | Moderate & Increasing | ||
| Ultrasound (HHUS) | ~ | Widely available | Widely Covered | |
| ABUS | Limited | Moderate & Increasing | ||
| Molecular Breast Imaging (MBI) | Estimated | Estimated | Limited | Limited (Emerging) |
| Contrast-Enhanced Mammography | ~ | ~ | Limited | Moderate & Increasing |
| Breast MRI | Limited | Widely Varies | ||
| Abbreviated MRI | Limited | Limited | ||
| IzoView Breast CT | (Target) | (Target) | Emerging | Favorable (Emerging) |
Market Opportunity and Displacement Potential
The global breast imaging device market is projected to grow from USD
Economic Value and Diagnostic Efficiency
From a health system perspective, IzoView addresses a major financial burden associated with current diagnostic imaging pathways. In the U.S. alone, approximately
A Platform for Expansion and Durable Competitive Advantage
From a competitive standpoint, IzoView sets a new benchmark in dedicated breast CT imaging. Two other breast CT systems are currently on the market, both representing early commercial entries into the modality. Based on non-public sources provided to the Company, one is priced at approximately USD
IzoView, in its current form, is uniquely suited to support advanced functions beyond adjunctive breast cancer screening with 14 identified potential future Indications for Use across five key areas of breast health: screening, diagnosis, monitoring, planning, and personalized medicine, with additional devices planned that expand upon IzoView’s core imaging platform. Many of these additional Indications for Use can be delivered after new clinical studies through software upgrades, creating strong incentives for early adopters as IzoView’s clinical utility increases without replacing the core system, creating a scalable upgrade path and recurring revenue model.
Intellectual Property Designed to Enable Long-Term Product Leadership
Izotropic continues to develop a strategically layered patent portfolio, designed to protect the most commercially and clinically significant aspects of the IzoView as a platform. Rather than focusing solely on imaging hardware, the portfolio focuses on a broad range of integrated capabilities, including image acquisition, data presentation, radiation safety, system usability, and workflow integration, reflecting how it can function as a complete solution for breast health in real-world healthcare environments. This approach makes it difficult for competitors to replicate IzoView’s full potential feature set and positions the Company for a durable competitive advantage across clinical settings.
The Company’s portfolio includes a mix of foundational patents and newer filings, with commercially relevant protections extending into the 2040s. In addition to patent claims, Izotropic has secured key innovations as trade secrets, such as its deep machine learning image reconstruction algorithm.
IzoView Is the Imaging Platform the Future of Breast Cancer Care Demands
IzoView is not simply an incremental improvement; it is a fundamental reimagining of what breast cancer imaging can and should be. It meets a well-defined and increasingly urgent clinical need, has the potential to deliver measurable improvements over the standard-of-care, can integrate into a broad range of healthcare environments, and offers a clear path to revenue growth and long-term expansion. As health systems evolve toward more personalized, risk-adapted, and patient-centric models of care, IzoView is uniquely positioned to become the cornerstone of next-generation breast imaging.
Source:
- (2024, December 9). Dense Breasts: Answers to Commonly Asked Questions. National Cancer Institute. Retrieved July 24, 2025, from https://www.cancer.gov/types/breast/breast-changes/dense-breasts
- Aminololama-Shakeri S, et al. Dedicated Breast CT: Getting Ready for Prime Time. J Breast Imaging. 2024. https://doi.org/10.1093/jbi/wbad099
- Aminololama-Shakeri S, et al. Dedicated Breast CT: Getting Ready for Prime Time. J Breast Imaging. 2024. https://doi.org/10.1093/jbi/wbad099
- (2025). Breast Imaging Market Global Forecast 2025-2030. 360i Research.
- Vlahiotis A, Griffin B, Stavros AT, Margolis J. Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography. Clinicoecon Outcomes Res. 2018;10:157-167 https://doi.org/10.2147/CEOR.S150260
About Izotropic:
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the target price of Izotropic's IzoView Breast CT system compared to competitors?
How does IZOZF's IzoView compare to traditional breast imaging technologies?
What is the market potential for Izotropic's IzoView breast imaging system?
How many future indications does Izotropic plan for the IzoView system?
What competitive advantages does IZOZF's IzoView system have?
